Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NVA Unveils Novel Pulmonary Drug Delivery Technology

Abstract:
Australian nanotechnology firm NanoVentures Australia (NVA) has reached an important milestone in technical development of its pulmonary drug delivery technology.

NVA Unveils Novel Pulmonary Drug Delivery Technology

Australia | Posted on June 1st, 2009

NVA's predecessor, Nanotechnology Victoria Ltd ("NanoVic") invested nearly $500,000 with Monash University's Micro NanoPhysics Research Laboratory to develop and demonstrate a novel mechanism for generation of liquid aerosol drugs. The proprietary SAW (Surface Acoustic Wave) generated mechanism allows fluids to be atomised as precisely controlled droplets, making them ideal for a new generation of inhaler devices. These inhalers are likely to be very low cost, as they require very few moving parts.

Further, the SAW technology means that drugs like insulin can be delivered in fluid droplet form from an inhaler. Previous attempts to deliver insulin from an inhaler have used dry powders, which are more difficult to control, and may cause new issues for certain groups of patients.

Last month, NVA and Monash University filed for the protection of new intellectual property around their proprietary pulmonary drug delivery device. The parties hold the Australian provisional patent application 2009902063 Microfluidics apparatus for the atomisation of a liquid. In particular the team has demonstrated in vitro results with maintenance of insulin structure and function after aerosolisation, and over 70% delivery to the lungs using the test protein insulin.

There has been growing interest in the potential for the systematic delivery of drugs and therapeutic agents (e.g. peptides and proteins) via inhalation. Pulmonary drug delivery is an attractive option compared to oral administration or other invasive delivery techniques, and is particularly suited to a number of frequent-application drugs. The surface acoustic atomisation technology developed by Monash University provides for the controlled generation of aerosol particles, and is ideal for drug delivery to the deep regions of the lungs.

NVA has exclusive rights to the exploitation of the technology for potential applications in the administration of insulin and erythropoietin, as well as for the treatment of Cystic Fibrosis and Multiple Sclerosis.

The delivery device R&D program, led by Associate Professor James Friend at the Monash University Micro NanoPhysics Research Laboratory, commenced in January 2007 and is due for completion in October 2009. Dr Friend is internationally known for his leadership in the application of nanotechnology to medical devices.

####

About NanoVentures Australia
NVA commercialises nanotechnologies developed by Nanotechnology Victoria Ltd (”NanoVic”), the Victorian Government funded nanotechnology accelerator which operated from 2002 to 2009. NVA has a portfolio of other technologies being positioned for commercial development, in medical therapeutics, diagnostics, advanced materials and water analysis and purification. NVA commercialises nanotechnologies developed by Nanotechnology Victoria Ltd (”NanoVic”), the Victorian Government funded nanotechnology accelerator which operated from 2002 to 2009.

For more information, please click here

Contacts:
Dr Michelle Critchley

Copyright © NanoVentures Australia

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Leti Presents Advances in Propagation Modeling and Antenna Design for mmWave Spectrum: Paper Is One of 15 that Leti Presented at European Conference on Antennas and Propagation March 19-24 March 23rd, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Products

STMicroelectronics Peps Up Booming Social-Fitness Scene with Smart Motion Sensors for Better Accuracy, Longer Battery Life, and Faster Time to Market January 2nd, 2017

Cutting-edge nanotechnologies are breaking into industries November 18th, 2016

STMicroelectronics’ Semiconductor Chips Contribute to Connected Toothbrush from Oral-B That Sees What You Don’t: Microcontroller and Accelerometer help brushers clean their teeth more effectively October 4th, 2016

Particle Works launches range of high quality magnetic nanoparticles August 31st, 2016

Possible Futures

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Investments/IPO's/Splits

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017

Nanomedicine

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

Announcements

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Intertronics introduce new nanoparticle deagglomeration technology March 15th, 2017

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016

Nanobiotechnology

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project